Genetic and Clinical Demographics of Adult Cystic Fibrosis Patients in a Middle Eastern Population

Irfan Shafiq1, Safia Shabeer2, Mateen Haider Uzbeck1, Zaid Zoumot1, Mohamed Abuzakouk1, Ali Saeed Wahla1

1Cleveland Clinic Abu Dhabi, Respiratory and Allergy Institute, Abu Dhabi, United Arab Emirates
2College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia

OBJECTIVE: Cystic fibrosis (CF) is the commonest life-limiting inherited illness in the Caucasian population but is uncommon in the Middle East, and so the genotypes and clinical course of disease in this population is not well known.

MATERIAL AND METHODS: In this retrospective observational study, we collected and reviewed the data on CF mutations, body mass index (BMI), lung function, microbiology, and the demographics in adult CF patients in the United Arab Emirates (UAE).

RESULTS: Data was reviewed for 39 adult CF patients. The median age of adult CF patients presenting to our clinic was 25 years (inter-quartile range (IQR) 22-31), the median BMI was 19 (IQR 17-22), and the median percentage predicted forced expiratory volume at 1 second (FEV1) was 49.5% (IQR 38.5-62.5). ΔF508 was the commonest mutation (n = 36, 92%), followed by S549R in 5 patients (13%). Only 5 (13%) out of 39 patients were heterozygote for CF mutations which reflects the high level of consanguinity in the region. Twelve (30%) patients were diagnosed after the age of 16, and in total, 19 (48%) were diagnosed after the age of 10. Thirty-two (82%) of patients are pseudomonas colonized, and 31% had 3 or more exacerbations in the last 12 months.

CONCLUSION: The CF mutation patterns in the UAE are different from western populations with low ΔF508 prevalence, with the presence of rare mutations more specific to this region and a high rate of homozygosity. Late diagnosis, high pseudomonas colonization rate, and exacerbation frequency remain a problem in this region and lead to poor long-term outcomes.

KEYWORDS: Cystic fibrosis, bronchiectasis, clinical epidemiology, rare lung diseases, pediatric lung disease

INTRODUCTION

Cystic fibrosis (CF) is the commonest inherited life-limiting illness among the Caucasian population¹ and is caused by mutations in the gene of CF transmembrane conductance regulator protein, located on the long arm of chromosome 7. The commonest known disease-causing mutation is ΔF508 which is reported in around 89% of patients in the United Kingdom (UK).² CF is thought to be an uncommon disease in the Middle East and the first case report of CF in this region was published in 1958 in a Lebanese child³ while the first reported case in UAE was in 1991.⁴ The estimated incidence of CF in UAE is thought to be around 1 in 15 000 live births.⁵ Unlike the western populations with well-established disease databases providing accurate incidence and prevalence data, the incidence estimates in the Middle East are deduced mostly from published case reports and hence are likely to be less accurate.

CF is a multisystem disease, with the most common cause of mortality being progressive bronchiectasis leading to chronic respiratory failure.⁶ CF survival has continued to improve in the western countries⁷ due to improvement in care provision and the advent of new treatment modalities, resulting in there being more adult CF patients than children. Although survival in middle eastern patients also seems to have improved, it has lagged significantly as compared to western nations; hence the adult CF patients in this region remain a minority. There have been few publications looking at the genetic and clinical parameters of CF patients in the UAE, and no published data on adult patients in this region is available. This lack of genetic and clinical demographic data makes it difficult to make long-term decisions about CF service development and clinical care. Moreover, the genetic mutations common in middle eastern patients are often different from the common mutations in the Caucasian populations and can vary significantly even within the various gulf countries.⁸ In this study, we present the CF mutation patterns and clinical parameters in the indigenous UAE adult population.

MATERIAL AND METHODS

This retrospective study was conducted at our adult pulmonary medicine department; the CF clinic here was established in 2015 and looks after almost all indigenous adult CF patients in the UAE. Approval from the local research ethics committee was obtained. All adult patients with the diagnosis of CF who attended our service between April 2015 and June 2019 were included in the study. The CF mutations testing was done by using a 97-mutation panel (Cystic Fibrosis Profile, 97 Mutations,
**RESULTS**

Data was reviewed for 39 adult CF patients (21 males, 18 females). The median age of adult CF patients presenting to our clinic was 25 years (IQR 22–31), the median BMI was 19 (IQR 17–22), and the median percentage predicted FEV1 was 49.5% (IQR 38.5–62.5) (Tables 1 and 2).

Figure 1 shows the mutations that were noted in our cohort. S549R mutation had the highest population frequency with 11 patients (28%) having at least 1 copy of it (10 homozygotes, 1 heterozygote) followed by ∆F508, which was present in 9 (23%) patients (8 homozygotes and 1 heterozygote). 3849+10 kbC>T mutation was also present in 9 patients but with more heterozygotes (5 homozygotes and 4 heterozygotes). We did not find any significant difference in terms of age, BMI, and FEV1 between the ∆F508 and non-∆F508 mutation carriers (Table 2). Most patients were heterozygotes for the CF mutations, and only 6 (15%) out of our 39 patients were homozygotes.

**MAIN POINTS**

- The CF is an uncommon disease in the Middle East and the mutation patterns in this population differ considerably from the Caucasian populations.
- Consanguinity leads to higher levels of homozygosity in this region.
- The clinical outcomes, although improving, have lagged significantly compared to developed western countries likely due to late diagnosis, high rates of pseudomonas colonization, and exacerbation rates.

| Table 1. Baseline Characteristics of the Study Population |
|-----------------------------------------------|
| **n**                                      |
| Total                                      | 39 |
| Males                                      | 21 (54%) |
| Females                                    | 18 (46%) |
| Comorbidities                              |
| Pancreatic insufficiency                    | 32 (82%) |
| CFRD                                        | 16 (41%) |
| CFRLD                                       | 6 (15%) |
| CFRBD                                       | 16 (41%) |
| Sinus disease                              | 20 (51%) |
| ABPA                                        | 6 (15%) |
| Depression                                 | 3 (8%) |
| DIOS                                        | 0 |
| Exacerbation frequency, wp/year             |
| 0                                           | 12 (31%) |
| 1                                           | 6 (15%) |
| 2                                           | 9 (23%) |

| BMI, body mass index; FEV1, forced expiratory volume in the first second; CFRD, cystic fibrosis-related diabetes; CFRLD, cystic fibrosis-related liver disease; CFRBD, cystic fibrosis-related bone disease; ABPA, allergic bronchopulmonary aspergillosis; DIOS, distal intestinal obstruction syndrome. |

Twelve (30%) patients were diagnosed after the age of 16, and in total, 19 (48%) were diagnosed after the age of 10. On review of microbiology results, 32 (82%) patients were found to be pseudomonas colonized, and methicillin-sensitive Staphylococcus aureus was the second most common colonizing organism (13 patients—33%) (Figure 2). The average exacerbation rate over the last 12 months was 1.74/patient, with 31% of the patients having 3 or more exacerbations in that period (Table 1).

Among the extra-pulmonary manifestations of the disease, pancreatic insufficiency was the commonest (82% of the patients) followed by symptomatic sinus disease (51%), CF-related diabetes (CFRD) and CF-related bone disease (CFRBD) were both present in 41% of the patients. Depression was reported by only 8%, and there were no cases of distal intestinal obstruction syndrome (DIOS) in our cohort. (Table 1).

Unfortunately, only 11 patients had completed the CFQ-R questionnaire in the last 12 months. The median scores for each domain of the questionnaire are listed in Table 3 in ascending order highlighting the respiratory, physical functioning, and treatment burden as the areas with the highest impact on the quality of life.

**DISCUSSION**

CF is an uncommon disease in the UAE, and there is a paucity of published data on the demographics of CF patients in the region. In this study, we present the genetic and clinical...
demographics of adult CF patients in the UAE, and below, we also compare our results to the CF Trust UK data to highlight the differences among the 2 populations.

FEV1 and BMI are important predictors of survival in CF9 and in our study population, we found these to be significantly lower than expected. To illustrate the point, we compare our results with the data from the UK CF trust’s 2018 report.2 Although our population is younger than the adult UK cohort, the median BMI for our patients was significantly lower (19 vs. 23.1).

Similarly, the percentage predicted FEV1 also was lower in our patients (49.5% vs. 71.1%). We also encountered a higher prevalence of chronic pseudomonas colonization in our patient population (32 patients 82% vs. 41.4% colonization in the adult UK population). Chronic pseudomonas colonization is associated with increased disease severity due to a higher exacerbation frequency and a decline in lung function.10 About one-third of the patients in our study had 3 or more exacerbations in the last 12 months which is at least partly due to the high pseudomonas colonization rate. Low FEV1 and BMI along with high pseudomonas colonization and exacerbation frequency highlight that the long-term prognosis of our cohort is likely to be worse than comparable patient cohorts in developed countries.

The only previously published data on CF genetics in the UAE was from Frossard et al. in 1998 who reported the genetic mutations of 16 CF patients and observed that all patients of Bedouin origin were homozygote for S549R (9 patients) while the patients of Al Balushi origin (7 patients) were ∆F508 homozygotes.11 We found a similar trend in our data as S549R was the commonest mutation followed by ∆F508, but we also discovered a significant number of patients with 3849+10 kbC>T mutation and several other less common or rare mutations. The presence of rare mutations and the lower incidence of ∆F508 mutation means that the common genetic mutation panels that test for a smaller number of common mutations are likely to be less useful in diagnosing CF in this region; therefore, if the clinical suspicion for CF is high, then one should have a low threshold for utilizing full

![Table 2](image)

| All Patients | ∆F508 | Non-∆F508 |
|-------------|-------|-----------|
| Mann–Whitney U test | P     |
| Age-years   | 25 (22-31) | 27 (22-30) | 26 (22-32) | 134 | .98 |
| BMI-kg/m²   | 19 (17-22) | 19.2 (17-20) | 20 (17-22) | 109 | .40 |
| FEV1-% Predicted | 49.5 (38.5-62.5) | 52.3 (39-56) | 47.3 (36-65) | 119 | .82 |

BMI, body mass index; FEV1, forced expiratory volume at 1 second.

![Figure 1](image)

Figure 1. Population frequency of CF mutations.

![Figure 2](image)

Figure 2. Prevalence of bacterial colonization.
In conclusion, CF is an uncommon and under-recognized disease in the UAE and among the adult patients, the prognosis seems to be significantly worse due to lower FEV1 and BMI as compared to their counterparts in the UK. This has been the largest cohort analysis of the CF patients in the UAE and among the adult patients, the prognosis seems to be significantly worse due to lower FEV1 and BMI as compared to their counterparts in the UK. Although it is useful to try and define the demographics of CF in the UAE, the retrospective observational nature of our study introduces certain limitations, out of which perhaps the most important is survivorship bias. Our study population includes only adults; hence it is possible that some patients with mutations associated with severe disease phenotypes may have died before transitioning to adult care, leaving a higher proportion of patients with mutations with milder disease phenotypes. Such a bias could result in the under-representation of class I and II mutations, including ΔF508. Since the pediatric CF population in the country is significantly larger, it would be useful to include all the CF patients in any future analysis to reduce the risk of bias and to improve the data accuracy. The development of a national or regional CF registry will be of paramount importance in conducting future epidemiological studies.

In conclusion, CF is an uncommon and under-recognized disease in the UAE and among the adult patients, the prognosis seems to be significantly worse due to lower FEV1 and BMI as compared to their counterparts in the UK. This has been the largest cohort analysis of the CF patients in the country and also highlights other important observations. First, the CF mutation patterns in the UAE are different from western populations with low ΔF508 prevalence, presence of rare mutations more specific to this region, and a high rate of homozygosity due to consanguinity. Late diagnosis remains at all. We hope that our study will help in choosing more region-specific mutation testing to be included in any future guidelines for neonatal screening. The true incidence of the disease is probably underestimated in the UAE, likely due to all the factors discussed above that lead to late diagnosis. Also, it is possible that some patients with severe illness may be dying without establishing the diagnosis while others with non-classical/mild CF may not get diagnosed till very late in adult life.

The prevalence of common CF-related comorbidities such as pancreatic insufficiency, CFRD, CF-related liver disease (CFRLD), and CFRBD in our study seems to be similar to the western populations. Perhaps the 2 notable differences in terms of comorbidities were the low levels of depression and DIOS. There were no cases of DIOS in our CF population which could be due to low ΔF508 prevalence. This lower prevalence of gastrointestinal symptoms was also reflected in the CFQ-R scores, with a high median score for the digestive symptom domain. Depression was reported by only 8%, which is probably a gross under-representation of the problem as patients often fail to report or admit to such symptoms due to the stigma associated with the psychiatric disease. We also find that reluctance to talk about psychological issues is also partly responsible for the lower number of patients agreeing to return the CFQ-R questionnaires. Although a lower number of patients completed the CFQ-R, it is unsurprising that the respiratory symptoms seem to have the highest impact on the quality of life closely followed by the physical disability and the treatment burden.

Although it is useful to try and define the demographics of CF in the UAE, the retrospective observational nature of our study introduces certain limitations, out of which perhaps the most important is survivorship bias. Our study population includes only adults; hence it is possible that some patients with mutations associated with severe disease phenotypes may have died before transitioning to adult care, leaving a higher proportion of patients with mutations with milder disease phenotypes. Such a bias could result in the under-representation of class I and II mutations, including ΔF508. Since the pediatric CF population in the country is significantly larger, it would be useful to include all the CF patients in any future analysis to reduce the risk of bias and to improve the data accuracy. The development of a national or regional CF registry will be of paramount importance in conducting future epidemiological studies.

In conclusion, CF is an uncommon and under-recognized disease in the UAE and among the adult patients, the prognosis seems to be significantly worse due to lower FEV1 and BMI as compared to their counterparts in the UK. This has been the largest cohort analysis of the CF patients in the country and also highlights other important observations. First, the CF mutation patterns in the UAE are different from western populations with low ΔF508 prevalence, presence of rare mutations more specific to this region, and a high rate of homozygosity due to consanguinity. Late diagnosis remains

| CFQ-R Domains          | Median Score (IQR) |
|------------------------|--------------------|
| Respiratory symptoms   | 44.4 (36.1-69.5)   |
| Physical functioning   | 54.2 (41.7-62.5)   |
| Treatment burden       | 55.6 (50-72.2)     |
| Social functioning     | 61.1 (52.8-69.5)   |
| Vitality               | 66.7 (41.7-75)     |
| Role functioning       | 66.7 (62.5-75)     |
| Weight                 | 66.7 (51.7-71.7)   |
| Emotional functioning  | 73.3 (43.3-90)     |
| Eating problems        | 77.8 (66.7-88.9)   |
| Health perceptions     | 77.8 (44.4-94.4)   |
| Body image             | 77.8 (53.6-77.8)   |
| Digestive symptoms    | 88.9 (83.3-100)    |

Table 3. CFQ-R Scores of the Study Population
a problem in the region and, along with high pseudomonas colonization rate and exacerbation frequency, lead to poor long-term outcomes.

**Ethics Committee Approval:** This study was approved by the Cleveland Clinic Abu Dhabi research ethics committee on 26 June 2018, (Protocol no. A-2018-024).

**Informed Consent:** Informed consent is not necessary due to the retrospective nature of this study.

**Peer Review:** Externally peer-reviewed.

**Author Contributions:** Supervision – I.S., S.S., A.S.W.; Design – I.S., S.S., M.H.U., Z.Z., M.A.; Resources – I.S., Z.Z., A.S.W.; Materials – I.S., A.S.W., M.H.U., S.S., M.A.; Data Collection and/or Processing – M.H.U., Z.Z., S.S.; Analysis and/or Interpretation – I.S., A.S.W., S.S., M.A.; Literature Search – Z.Z., M.H.U.; Writing Manuscript – I.S., S.S., A.S.W.; Critical Review – A.S.W., M.A., Z.Z.

**Conflict of Interest:** The authors have no conflict of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**REFERENCES**

1. Davies JC, Alton EWFW, Bush A. Cystic fibrosis. BMJ. 2007;335:1255-1259. [CrossRef]
2. UK Cystic Fibrosis Registry Annual Data Report. https://www.cysticfibrosis.org.uk; 2018;2019.
3. Salam MZ. Cystic fibrosis of the pancreas in an oriental child. Ann Paediatr Int Rev Pediatr. 1958;190:252-255.
4. El Gohary A, Salem FA, Aziz SA. Cystic fibrosis in the UAE. Emirates Med J. 1991;9:202-204.
5. Frossard PM, Lestringant G, Girodon E, Goossens M, Dawson KP. Determination of the prevalence of cystic fibrosis in the united arab emirates by genetic carrier screening. Clin Genet. 1999;55:496-497. [CrossRef]
6. Mackenzie T, Gifford AH, Sabadosa KA et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the cystic fibrosis foundation patient registry. Ann Intern Med. 2014;161:233-241. [CrossRef]
7. Stephenson AL, Sykes J, Stanojevic S et al. Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study. Ann Intern Med. 2017;166:537-546. [CrossRef]
8. Banjar H, Angyalosi G. The road for survival improvement of cystic fibrosis patients in arab countries. Int J Pediatr Adolesc Med. 2015;2:47-58. [CrossRef]
9. Sharma R, Florea VG, Bolger AP et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax. 2001;56:746-750. [CrossRef]
10. Hector A, Kirn T, Ralhan A et al. Microbial colonization and lung function in adolescents with cystic fibrosis. J Cyst Fibros. 2016;15:340-349. [CrossRef]
11. Frossard PM, Girodon E, Dawson KP et al. Identification of cystic fibrosis mutations in the united arab emirates. Mutations in brief no. 133. Hum Mutat. 1998;11:412-413. [CrossRef]
12. Rodman DM, Polis JM, Heltshe SL et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2005;171:621-626. [CrossRef]
13. Green A, Isnerwood D, Pollitt R. Cystic_Fibrosis_Lab_Guide_February_2014_v1.0_12_.pdf [Internet]. Accessed 2020 Jan 24. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/397726/Cystic_Fibrosis_Lab_Guide_February_2014_v1.0_12_.pdf.